Validation of PCR-RFLP techniques for the evaluation of codon 72 of p53 and CYP1A1 gene's polymorphisms in relation with ovarian cancer in a Romanian population

Romanian Journal of Morphology and Embryology

Volumn 53, Issue 1, 2012, Pages 47-54

  Matei, Mioara Calipsoana ^a   Negura L ^a   Liliac, Ludmila ^a   Negurǎ, Anca ^b   Azoicǎi, Doina ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

Author keywords

CYP1A1 polymorphism; Ovarian cancer; p53 polymorphism; Risk factors

Indexed keywords

CYP1A1 PROTEIN, HUMAN; CYTOCHROME P450 1A1; PROTEIN P53; TP53 PROTEIN, HUMAN;

ALLELE; ARTICLE; BIOLOGICAL MODEL; CASE CONTROL STUDY; CODON; COMPUTER PROGRAM; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; HUMAN GENOME; METHODOLOGY; OVARY TUMOR; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE;

ALLELES; CASE-CONTROL STUDIES; CODON; CYTOCHROME P-450 CYP1A1; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; MODELS, GENETIC; MODELS, STATISTICAL; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; SOFTWARE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857960870     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hussain SP, Harris CC, Molecular epidemiology of human cancer, Toxicol Lett, 1998, 102-103:219-225.
2. Vineis P, Matullo G, Berwick M, Molecular epidemiology. In: Ahrens W, Pigeot I (eds), Handbook of Epidemiology, Springer-Verlag, Bremen, 2006.
3. Negurà A, Matei M, Negurà L, Carasevici E, Uhrhammer N, Bignon YJ, Azoicài D, Ethical implications of communicating molecular test results to families with hereditary predisposition to cancer, Rev Rom Bioet, 2010, 8(4):156-165.
4. Hayashi S, Watanabe J, Nakachi K, Kawajiri K, Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene, J Biochem, 1991, 110(3):407-411.
5. Oyama T, Mitsudomi T, Kawamoto T, Ogami A, Osaki T, Kodama Y, Yasumoto K, Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese, Int Arch Occup Environ Health, 1995, 67(4):253-256.
6. Amikura T, Sekine M, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, Nagata I, Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto T, Motoyama S, Nishino K, Haino K, Tanaka K; Japanese Familial Ovarian Cancer Study Group, Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan, Gynecol Oncol, 2006, 100(2):365-371.
7. Sugawara T, Nomura E, Sagawa T, Sakuragi N, Fujimoto S, CYP1A1 polymorphism and risk of gynecological malignancy in Japan, Int J Gynecol Cancer, 2003, 13(6):785-790.
8. Ueda M, Terai Y, Kanda K, Kanemura M, Takehara M, Yamaguchi H, Nishiyama K, Yasuda M, Ueki M, Germline polymorphism of p53 codon 72 in gynecological cancer, Gynecol Oncol, 2006, 100(1):173-178.
9. Ara S, Lee PS, Hansen MF, Saya H, Codon 72 polymorphism of the TP53 gene, Nucleic Acids Res, 1990, 18(16):4961.
10. Agorastos T, Masouridou S, Lambropoulos AF, Chrisafi S, Miliaras D, Pantazis K, Constantinides TC, Kotsis A, Bontis I, P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women, Eur J Cancer Prev, 2004, 13(4):277-280.
11. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S, The CYP1A1 gene and cancer susceptibility, Crit Rev Oncol Hematol, 1993, 14(1):77-87.
12. Aktas D, Guney I, Alikasifoglu M, Yüce K, Tuncbilek E, Ayhan A, CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm, Gynecol Oncol, 2002, 86(2):124-128.
13. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih IeM, Wang TL, Amplicon profiles in ovarian serous carcinomas, Int J Cancer, 2007, 120(12):2613-2617.
14. Matei M, Negurà L, Carasevici E, Azoicài D, Specifics of individual risks in a group of women with genital neoplasms, Rev Med Chir Soc Med Nat Iaşi, 2009, 113(4):1216-1221.
15. Negura L, Uhrhammer N, Negura A, Artenie V, Carasevici E, Bignon YJ, Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population, Fam Cancer, 2010, 9(4):519-523.
16. Pegoraro RJ, Moodley M, Rom L, Chetty R, Moodley J, P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans, Int J Gynecol Cancer, 2003, 13(4):444-449.
17. Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA, Chakraborty R, Rothhammer F, p53 codon 72 polymorphism and risk of cervical cancer, Biol Res 2003, 36(2):279-283.
18. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A, Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma, Hum Mutat, 2004, 24(1):21-34.
19. Shih IeM, Kurman RJ, Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis, Am J Pathol, 2004, 164(5):1511-1518.